Patrick Bruneval
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Patrick Bruneval has a total of 741 co-authors. Here are the top co-authors by number of shared publications:
Alexandre Loupy
Team Inflammation Complement and Cancer, Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université Paris Cité, Paris, France
6 shared publications- Bijan Ghaleh
Inserm, U955, Equipe 03, F-94000 Créteil, France
6 shared publications - Renaud Tissier
Netherlands Cancer Institute
6 shared publications - Alexandre Loupy
INSERM, PARCC, Paris Institute for Transplantation and Organ Regeneration, Université de Paris Cité, Paris, France
4 shared publications - Arshid Azarine
Department of Radiology, Hôpital Marie Lannelongue, Fondation Paris Saint-Joseph, 133 avenue de la Résistance, Le Plessis-Robinson 92350, France
4 shared publications - Guillaume Coutance
University of Paris Cité, INSERM UMR 970, Paris Translational Research Centre for Organ Transplantation, Paris, France; Department of Cardiac Surgery, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP). Paris Cité University Medical School, Paris, France
4 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 124, 119-128
Histopathologic patterns of iatrogenic arterial wall injury in thrombosed free-flap microanastomoses
- 29 October 2026
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 124, 119-128
Open AccessHistopathologic patterns of iatrogenic arterial wall injury in thrombosed free-flap microanastomoses
- 4 June 2026
- Published by Springer Nature in Nature
- Vol. 654 (8120) , E29
Author Correction: Physiology and immunology of a pig-to-human decedent kidney xenotransplant
- 4 June 2026
- Published by Springer Nature in Nature
- Vol. 654 (8120) , E29
Author Correction: Physiology and immunology of a pig-to-human decedent kidney xenotransplant
- Open Access
- 14 April 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (7) , 1561-1576
Pathologic Evaluation of Pig Kidney and Heart Xenografts: 2024 Recommendations from the Banff Xenotransplantation Pathology Working Group
- 14 April 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (7) , 1561-1576
Open AccessPathologic Evaluation of Pig Kidney and Heart Xenografts: 2024 Recommendations from the Banff Xenotransplantation Pathology Working Group
- Open Access
- 1 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
NK cells promote cardiac cell death and regulate myelopoiesis in myocardial infarction
Ischemic heart failure remains a major clinical challenge, underscoring the need to better understand post-infarction immune mechanisms and identify new therapeutic targets. Both innate and adaptive immunity contribute to adverse cardiac remodeling following myocardial infarction (MI), yet the role of cytotoxic cells such as natural killer (NK) cells remains poorly defined. Here, we show that after acute MI in mice, NK cells are recruited to the ischemic myocardium in a CCR2-dependent manner and become activated. Activated NK cells locally release granzyme B, promoting cardiomyocyte apoptosis, adverse ventricular remodeling, and impaired cardiac function. Genetic deletion or pharmacological depletion of NK cells reduces cardiomyocyte death, attenuates inflammation, limits myocardial injury, and improves cardiac function. In contrast, NK cell activation using an anti-NKG2A monoclonal antibody exacerbates ischemic heart failure. We further demonstrate that NK cells regulate bone marrow myelopoiesis through local GM-CSF production. Finally, we identify a distinct NK cellular and transcriptomic signature in human ischemic heart tissue at early stages. Together, these findings reveal a detrimental role for NK cells following acute MI and highlight NK cells as potential therapeutic targets to limit adverse cardiac remodeling.
- 1 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessNK cells promote cardiac cell death and regulate myelopoiesis in myocardial infarction
Ischemic heart failure remains a major clinical challenge, underscoring the need to better understand post-infarction immune mechanisms and identify new therapeutic targets. Both innate and adaptive immunity contribute to adverse cardiac remodeling following myocardial infarction (MI), yet the role of cytotoxic cells such as natural killer (NK) cells remains poorly defined. Here, we show that after acute MI in mice, NK cells are recruited to the ischemic myocardium in a CCR2-dependent manner and become activated. Activated NK cells locally release granzyme B, promoting cardiomyocyte apoptosis, adverse ventricular remodeling, and impaired cardiac function. Genetic deletion or pharmacological depletion of NK cells reduces cardiomyocyte death, attenuates inflammation, limits myocardial injury, and improves cardiac function. In contrast, NK cell activation using an anti-NKG2A monoclonal antibody exacerbates ischemic heart failure. We further demonstrate that NK cells regulate bone marrow myelopoiesis through local GM-CSF production. Finally, we identify a distinct NK cellular and transcriptomic signature in human ischemic heart tissue at early stages. Together, these findings reveal a detrimental role for NK cells following acute MI and highlight NK cells as potential therapeutic targets to limit adverse cardiac remodeling.
- Open Access
- 12 February 2026
- Published by Springer Nature in Nature
- Vol. 651 (8104) , E4
Publisher Correction: Physiology and immunology of a pig-to-human decedent kidney xenotransplant
- 12 February 2026
- Published by Springer Nature in Nature
- Vol. 651 (8104) , E4
Open AccessPublisher Correction: Physiology and immunology of a pig-to-human decedent kidney xenotransplant
- Top Cited Papers
- 13 November 2025
- Published by Springer Nature in Nature
- Vol. 650 (8100) , 218-229
Physiology and immunology of a pig-to-human decedent kidney xenotransplant
Xenotransplantation of genetically-modified pig kidneys offers a solution to the scarcity of organs for end-stage renal disease patients.1 We performed a 61-day alpha-Gal knock-out pig kidney and thymic autograft transplant into a nephrectomized brain-dead human using clinically approved immunosuppression, without CD40 blockade or additional genetic modification. Hemodynamic and electrolyte stability and dialysis independence were achieved. Post-operative day (POD) 10 biopsies revealed glomerular IgM and IgA deposition, activation of early complement components and mesangiolysis with stable renal function without proteinuria, a phenotype not seen in allotransplantation. On POD 33, an abrupt increase in serum creatinine was associated with antibody-mediated rejection and increased donor-specific IgG. Plasma exchange, C3/C3b inhibition and rabbit anti-thymocyte globulin (rATG), completely reversed xenograft rejection. Pre-existing donor-reactive T cell clones expanded progressively in the circulation post-transplant, acquired an effector transcriptional profile and were detected in the POD 33 rejecting xenograft prior to rATG treatment. This study provides the first long-term physiologic, immunologic, and infectious disease monitoring of a pig-to-human kidney xenotransplant and indicates that pre-existing xenoreactive T cells and induced antibodies to unknown epitope(s) present a major challenge, despite significant immunosuppression. It also demonstrates that a minimally gene-edited pig kidney can support long-term life-sustaining physiologic functions in a human.
- 13 November 2025
- Published by Springer Nature in Nature
- Vol. 650 (8100) , 218-229
Top Cited PapersPhysiology and immunology of a pig-to-human decedent kidney xenotransplant
Xenotransplantation of genetically-modified pig kidneys offers a solution to the scarcity of organs for end-stage renal disease patients.1 We performed a 61-day alpha-Gal knock-out pig kidney and thymic autograft transplant into a nephrectomized brain-dead human using clinically approved immunosuppression, without CD40 blockade or additional genetic modification. Hemodynamic and electrolyte stability and dialysis independence were achieved. Post-operative day (POD) 10 biopsies revealed glomerular IgM and IgA deposition, activation of early complement components and mesangiolysis with stable renal function without proteinuria, a phenotype not seen in allotransplantation. On POD 33, an abrupt increase in serum creatinine was associated with antibody-mediated rejection and increased donor-specific IgG. Plasma exchange, C3/C3b inhibition and rabbit anti-thymocyte globulin (rATG), completely reversed xenograft rejection. Pre-existing donor-reactive T cell clones expanded progressively in the circulation post-transplant, acquired an effector transcriptional profile and were detected in the POD 33 rejecting xenograft prior to rATG treatment. This study provides the first long-term physiologic, immunologic, and infectious disease monitoring of a pig-to-human kidney xenotransplant and indicates that pre-existing xenoreactive T cells and induced antibodies to unknown epitope(s) present a major challenge, despite significant immunosuppression. It also demonstrates that a minimally gene-edited pig kidney can support long-term life-sustaining physiologic functions in a human.
- Top Cited PapersOpen Access
- 18 July 2025
- Published by Springer Nature in Nature
- Vol. 644 (8076) , 516-526
Pathology-oriented multiplexing enables integrative disease mapping
The expression and location of proteins in tissues represent key determinants of health and disease. Although recent advances in multiplexed imaging have expanded the number of spatially accessible proteins1–3, the integration of biological layers (that is, cell structure, subcellular domains and signalling activity) remains challenging. This is due to limitations in the compositions of antibody panels and image resolution, which together restrict the scope of image analysis. Here we present pathology-oriented multiplexing (PathoPlex), a scalable, quality-controlled and interpretable framework. It combines highly multiplexed imaging at subcellular resolution with a software package to extract and interpret protein co-expression patterns (clusters) across biological layers. PathoPlex was optimized to map more than 140 commercial antibodies at 80 nm per pixel across 95 iterative imaging cycles and provides pragmatic solutions to enable the simultaneous processing of at least 40 archival biopsy specimens. In a proof-of-concept experiment, we identified epithelial JUN activity as a key switch in immune-mediated kidney disease, thereby demonstrating that clusters can capture relevant pathological features. PathoPlex was then used to analyse human diabetic kidney disease. The framework linked patient-level clusters to organ disfunction and identified disease traits with therapeutic potential (that is, calcium-mediated tubular stress). Finally, PathoPlex was used to reveal renal stress-related clusters in individuals with type 2 diabetes without histological kidney disease. Moreover, tissue-based readouts were generated to assess responses to inhibitors of the glucose cotransporter SGLT2. In summary, PathoPlex paves the way towards democratizing multiplexed imaging and establishing integrative image analysis tools in complex tissues to support the development of next-generation pathology atlases.
- 18 July 2025
- Published by Springer Nature in Nature
- Vol. 644 (8076) , 516-526
Top Cited PapersOpen AccessPathology-oriented multiplexing enables integrative disease mapping
The expression and location of proteins in tissues represent key determinants of health and disease. Although recent advances in multiplexed imaging have expanded the number of spatially accessible proteins1–3, the integration of biological layers (that is, cell structure, subcellular domains and signalling activity) remains challenging. This is due to limitations in the compositions of antibody panels and image resolution, which together restrict the scope of image analysis. Here we present pathology-oriented multiplexing (PathoPlex), a scalable, quality-controlled and interpretable framework. It combines highly multiplexed imaging at subcellular resolution with a software package to extract and interpret protein co-expression patterns (clusters) across biological layers. PathoPlex was optimized to map more than 140 commercial antibodies at 80 nm per pixel across 95 iterative imaging cycles and provides pragmatic solutions to enable the simultaneous processing of at least 40 archival biopsy specimens. In a proof-of-concept experiment, we identified epithelial JUN activity as a key switch in immune-mediated kidney disease, thereby demonstrating that clusters can capture relevant pathological features. PathoPlex was then used to analyse human diabetic kidney disease. The framework linked patient-level clusters to organ disfunction and identified disease traits with therapeutic potential (that is, calcium-mediated tubular stress). Finally, PathoPlex was used to reveal renal stress-related clusters in individuals with type 2 diabetes without histological kidney disease. Moreover, tissue-based readouts were generated to assess responses to inhibitors of the glucose cotransporter SGLT2. In summary, PathoPlex paves the way towards democratizing multiplexed imaging and establishing integrative image analysis tools in complex tissues to support the development of next-generation pathology atlases.
- 26 March 2025
- Published by Oxford University Press (OUP) in Rheumatology
Immune checkpoint inhibitors–induced large vessel vasculitis: clinical characteristics and management from a European multicentre study
Objective: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but frequently cause immune-related adverse events (IrAEs). ICI-induced large vessel vasculitis (LVV) is a rare IrAE, with limited available data. We aimed to describe and compare clinical characteristics and evolution of ICI-induced LVV to primary LVV. Methods: This retrospective, multicentre European study included adult patients who developed LVV after ICI therapy between March 2018 and August 2024. Patients were compared with matched controls with primary LVV. LVV was defined histologically and/or morphologically. Results: Twenty-seven patients were included [median (interquartile range) age 68 (61–74) years]. Five (19%) had a history of polymyalgia rheumatica or GCA. Median time from ICIs initiation to LVV diagnosis was 3 (2–17) months. Eight patients (30%) received ipilimumab–nivolumab combination therapy, all of whom developed LVV within 6 months. Most clinical features were similar to matched controls, however PET scan diagnosis and large-vessel involvement were more common in ICI-induced LVV. Visual loss occurred in 4 (15%) patients. Management included discontinuation of ICIs in 19 (70%) patients and administration of glucocorticoids. After a median follow-up of 12 (5–20) months, 20 (74%) achieved sustained remission. Relapse or treatment failure of LVV occurred in 3/9 (33%) patients who continued ICIs and 4/18 (22%) who discontinued them. By last follow-up, 9 (33%) patients had died, mainly from cancer (n = 8). Conclusion: ICI-induced LVV is a rare, early-onset IrAE. Although continuation of ICIs may affect LVV outcomes, cancer progression remains the primary cause of mortality. Prospective studies are warranted to better balance therapeutic approaches.
- 26 March 2025
- Published by Oxford University Press (OUP) in Rheumatology
Immune checkpoint inhibitors–induced large vessel vasculitis: clinical characteristics and management from a European multicentre study
Objective: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but frequently cause immune-related adverse events (IrAEs). ICI-induced large vessel vasculitis (LVV) is a rare IrAE, with limited available data. We aimed to describe and compare clinical characteristics and evolution of ICI-induced LVV to primary LVV. Methods: This retrospective, multicentre European study included adult patients who developed LVV after ICI therapy between March 2018 and August 2024. Patients were compared with matched controls with primary LVV. LVV was defined histologically and/or morphologically. Results: Twenty-seven patients were included [median (interquartile range) age 68 (61–74) years]. Five (19%) had a history of polymyalgia rheumatica or GCA. Median time from ICIs initiation to LVV diagnosis was 3 (2–17) months. Eight patients (30%) received ipilimumab–nivolumab combination therapy, all of whom developed LVV within 6 months. Most clinical features were similar to matched controls, however PET scan diagnosis and large-vessel involvement were more common in ICI-induced LVV. Visual loss occurred in 4 (15%) patients. Management included discontinuation of ICIs in 19 (70%) patients and administration of glucocorticoids. After a median follow-up of 12 (5–20) months, 20 (74%) achieved sustained remission. Relapse or treatment failure of LVV occurred in 3/9 (33%) patients who continued ICIs and 4/18 (22%) who discontinued them. By last follow-up, 9 (33%) patients had died, mainly from cancer (n = 8). Conclusion: ICI-induced LVV is a rare, early-onset IrAE. Although continuation of ICIs may affect LVV outcomes, cancer progression remains the primary cause of mortality. Prospective studies are warranted to better balance therapeutic approaches.
- Open Access
- 12 October 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (4) , 533-541
Report of the 2022 Banff Heart Concurrent: Focus on non-human leukocyte antigen antibodies in rejection and the pathology of “mixed” rejection
- 12 October 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (4) , 533-541
Open AccessReport of the 2022 Banff Heart Concurrent: Focus on non-human leukocyte antigen antibodies in rejection and the pathology of “mixed” rejection
- 23 July 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (11) , 1505-1509
Validation of the clinical utility of microRNA as noninvasive biomarkers of cardiac allograft rejection: A prospective longitudinal multicenter study
- 23 July 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (11) , 1505-1509
Validation of the clinical utility of microRNA as noninvasive biomarkers of cardiac allograft rejection: A prospective longitudinal multicenter study